2019 was all about execution for smaller device makers
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
Led by Tandem, small-cap medtechs pump up the value in 2018
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Neurostimulation sham scuppers Mainstay
Mainstay Medical still hopes for US approval of its Reactiv8 device for chronic back pain despite trial failure.
Lack of takeovers sees medtech hiring staff again
Intuitive Surgical is the winner in terms of sales per employee, despite increasing its headcount 17%.
